RECOMMENDATIONS:
Level 2: WBRT is not recommended in WHO performance status 0 to 2 patients with up to 4 brain metastases because, compared to surgical resection or radiosurgery alone, the addition of WBRT improves intracranial progression-free survival but not overall survival. Level 2: In WHO performance status 0 to 2 patients with up to 4 brain metastases where the goal is minimizing neurocognitive toxicity, as opposed to maximizing progressionfree survival and overall survival, local therapy (surgery or radiosurgery) without WBRT is recommended. Level 3: Compared to surgical resection or radiosurgery alone, the addition of WBRT is not recommended for patients with more than 4 brain metastases unless the metastases' volume exceeds 7 cc, or there are more than 15 metastases, or the size or location of the metastases are not amenable to surgical resection or radiosurgery. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-treatmentadults-metastatic-brain-tumors/chapter_3. www.neurosurgery-online.com W hole brain radiation therapy (WBRT) has long been a standard treatment for patients with brain metastases. Based on preclinical and observational data, some physicians alter dose fractionation or withhold WBRT based on tumor histology. Concern has also been expressed by clinicians regarding the neurocognitive effects of WBRT, particularly if the metastases are amenable to surgical resection or stereotactic radiosurgery.
This guideline is based on a systematic review of the evidence available for WBRT dose fractionation regimens, the impact of tumor histopathology, prior surgery or stereotactic radiosurgery and neurocognitive toxicity on treatment outcomes when WBRT is used for newly diagnosed brain metastases.
METHODS
To update questions raised in the prior guidelines, 1 the PubMed, Embase, and Cochrane CENTRAL databases were searched for the period from January 1, 2008 to December 31, 2015. For the new question regarding neurocognitive effects, the search extended from January 1, 1990 through December 31, 2015. A broad search strategy using a combination of controlled vocabulary and text words was employed. The selected articles were classified according to criteria for evidence on prognosis as detailed in the Joint Guidelines Review Committee (JGRC) Guideline Development 
RESULTS
A total of 1823 articles were screened, of which 14 studies (9 class III, 3 class II, and 2 class III) lead to the recommendations regarding the optimal dose/fractionation of WBRT. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] To decrease neurocognitive toxicity, local therapy (surgery or SRS) without WBRT is recommended for patients with <4 brain metastases amenable to local therapy in terms of size and location. WBRT doses exceeding 30 Gy given in 10 fractions, or similar biologically equivalent doses, are not recommended, except in patients with poor performance status or limited survival. If WBRT is given to prevent brain metastases, the recommended WBRT dose/fractionation regimen is 25 Gy in 10 fractions. Patients receiving WBRT should be offered 6 mo of memantine to potentially delay, lessen, or prevent the associated neurocognitive toxicity.
Of the literature screened, relevant class II and III studies showed no preference for a particular dose/fractionation regimen based on histopathology or molecular status. [16] [17] [18] [19] To examine the neurocognitive consequences of WBRT, and whether steps can be taken to minimize them, there were 13 studies (2 class I, 9 class II, and 2 class III) to inform the recommendations. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Neurocognitive decline following WBRT given in 2.0-3.0 Gy daily fractions appears to be correlated with total delivered dose, so the lower total dose is recommended. Class I evidence shows a non-significant trend towards neurocognitive protection with memantine in patients undergoing WBRT. 30 This supports the level 3 recommendation to place patients E160 | VOLUME 84 | NUMBER 3 | MARCH 2019
www.neurosurgery-online.com having WBRT (given for either existing brain metastases or as prophylactic cranial irradiation) on 6 mo of memantine to potentially decrease associated neurocognitive toxicity. Class II evidence suggests that hippocampal avoidance may significantly reduce the risk of neurocognitive decline compared with conventional WBRT. 31 The question as to whether the addition of WBRT after surgical resection or radiosurgery improves progression-free or overall survival outcomes when compared to surgical resection or radiosurgery alone was addressed in 3 articles: 1 class I, 1 class II, and 1 class III. [33] [34] [35] Compared to surgical resection or radiosurgery alone, WBRT improves intracranial progression-free survival but not overall survival in patients with 4 or fewer brain metastases yielding a limited level 2 recommendation to not proceed to WBRT in WHO performance status 0 to 2 patients with up to 4 brain metastases. However, local therapy alone is associated with a higher incidence of both local and distant intracranial tumor recurrence, and prospective randomized studies in patients with more than 4 brain metastases have not been conducted. This supports the following level 3 recommendation that the addition of WBRT is not recommended for patients with more than 4 brain metastases unless the metastases' volume, number, size, or location does not make them amenable to surgical resection or radiosurgery.
DISCUSSION
The use of WBRT has declined over the past 10 yr as the use of local and systemic therapies has evolved. Clinicians appropriately raise the question of when should WBRT be used. Though the above recommendations shed some light on this, studies with improved measures of neurocognitive outcome, attention to histopathologic and molecular subtypes, and timing of WBRT related to local and systemic therapies are necessary for better answers to this question. The amelioration of neurocognitive impairment by memantine appears promising and warrants additional investigation as do hippocampal avoidance techniques when creating treatment plans.
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